RxDoctor Payments Data

Paul Johnson, MD

Ophthalmic Plastic and Reconstructive Surgery · Philadelphia, PANPI 1669529780

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 65.9% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $385, more than ten times the $13 reported in 2019.

$786in general payments, 2019–2025

Across 29 payments — averaging $27.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$518
  • Surgical Specialties Corporation (US), Inc. (dba Corza Medical)$84
  • Sight Sciences, Inc.$75
  • Bausch & Lomb Americas Inc.$46
  • Inspire Medical Systems, Inc.$39
  • AbbVie$24

What the payments were for

  • Food & beverage$786100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$222,400
Medicare patients
348
Services billed
1,545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TobradexTobramycin/Dexamethasone20$5,291
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha406$4,530
Doxycycline Hyclate22$1,030
ErythromycinErythromycin Base68$724
Methylprednisolone96$448
MoxifloxacinMoxifloxacin Hcl11$152
Acetaminophen-CodeineAcetaminophen With Codeine18$48

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →